Onconetix (ONCO) EBIT (2021 - 2026)
Onconetix (ONCO) posted quarterly EBIT of -$10.2 million for Q1 2026, up 18.65% year-over-year from -$8.6 million in Q1 2025, and down 698.04% quarter-over-quarter from -$1.3 million in Q4 2025.
Onconetix (ONCO) EBIT (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported EBIT for 6 consecutive years, with -$10.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 18.65% year-over-year to -$10.2 million; the TTM figure through Mar 2026 stood at -$15.5 million (up 73.25% YoY), while the FY2025 annual figure was -$17.9 million, up 68.39% from the prior year.
- EBIT slipped to -$10.2 million in Q1 2026 per ONCO's latest filing, from -$1.3 million in the prior quarter.
- Across five years, EBIT topped out at -$1.3 million in Q4 2025 and bottomed at -$29.1 million in Q4 2024.
- Historically, EBIT has averaged -$7.9 million across 5 years, with a median of -$4.3 million in 2022.
- Annual changes were most pronounced in 2023 — EBIT slumped 579.26% — and 2025, when it surged 95.6%.
- Onconetix's EBIT stood at -$3.2 million in 2022, then plunged by 579.26% to -$22.0 million in 2023, then tumbled by 32.19% to -$29.1 million in 2024, then soared by 95.6% to -$1.3 million in 2025, then slumped by 698.04% to -$10.2 million in 2026.
- Business Quant data shows ONCO's EBIT at -$10.2 million in Q1 2026, -$1.3 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 133.12 Mn |
| 10 | Onconetix | 1.44 Mn | -4.51 Mn | 4,303.00 | -2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.73 Mn |
| Mar 31, 2026 | -10.23 Mn |
| Dec 31, 2025 | -1.28 Mn |
| Sep 30, 2025 | -2.07 Mn |
| Jun 30, 2025 | -1.94 Mn |
| Mar 31, 2025 | -12.57 Mn |
| Dec 31, 2024 | -29.15 Mn |
| Sep 30, 2024 | -2.65 Mn |
| Jun 30, 2024 | -13.62 Mn |
| Mar 31, 2024 | -11.08 Mn |
| Dec 31, 2023 | -22.05 Mn |
| Sep 30, 2023 | -4.49 Mn |
| Jun 30, 2023 | -6.65 Mn |
| Mar 31, 2023 | -2.85 Mn |
| Dec 31, 2022 | -3.25 Mn |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -4.29 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | -1.20 Mn |
| Sep 30, 2021 | -1.10 Mn |